Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells

Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells for Leukemia Research

Our Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells is a hematopoietic tissue sample isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples are sourced from IRB-consented donors clinically diagnosed with AML, an aggressive myeloid malignancy defined by marrow blast accumulation.

AML Biology and Why Bone Marrow

• AML diagnosis requires a marrow myeloblast count of 20% or greater (per WHO criteria), making bone marrow aspirate the required diagnostic specimen rather than peripheral blood, which may not reflect true marrow blast burden.
• Cytogenetic and molecular risk stratification – including FLT3-ITD, NPM1, CEBPA, and TP53 status – is performed on marrow aspirate and directly informs treatment intensity and eligibility for targeted therapies.
• Minimal residual disease (MRD) assessment by flow cytometry or molecular methods on post-treatment marrow is a key determinant of relapse risk and consolidation strategy.
• Targeted agents including FLT3 inhibitors, IDH1/2 inhibitors, and venetoclax-based regimens have made marrow-derived blast material essential for pharmacodynamic and resistance-mechanism studies.
• Marrow stromal and microenvironment interactions are an active area of research into AML chemoresistance and relapse.

Donor Stratification Available

• Cytogenetic and molecular risk group (favorable, intermediate, adverse)
• Key mutation status where documented: FLT3, NPM1, CEBPA, TP53, IDH1/2
• Disease phase: newly diagnosed, post-induction, relapsed/refractory
• Blast percentage at collection where available
• Treatment history, including targeted agents or stem cell transplant
• Age band and sex assigned at birth
• Matched healthy bone marrow controls available

Product Features

• Isolated from clinically confirmed AML donor bone marrow aspirate
• Density-gradient purified and cryopreserved
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom cell quantities available

De-identified Donor Data

• AML diagnosis confirmation and cytogenetic/molecular subtype where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history and disease phase where documented
• Additional AML-specific metadata available on request

Applications

• Minimal residual disease (MRD) detection and monitoring assay development
• FLT3, NPM1, and other molecular marker studies
• Targeted therapy pharmacodynamic and resistance-mechanism research
• Blast immunophenotyping studies
• Marrow microenvironment and chemoresistance research

Other Specimen Types

For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

AML bone marrow mononuclear cells are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.